english.prescrire.org > Topics > Advancing healthcare policy > Advancing healthcare policy in Europe: a chronological recap of actions > 2015 Recap

Advancing healthcare policy

Advancing healthcare policy in Europe: a chronological recap of actions

Advancing healthcare policy

Chronological recap of actions
Actions presented by theme

A recap of actions in 2015

Working together with other organisations, Prescrire's policy advocacy is a source of constructive proposals, counterbalancing the influence of purely commercial interests.

A PRIME example of how EMA is pushing for accelerated market approvals, but at what cost for patients? (December 2015)

Joint response by ISDB, HAI, MiEF, the Mario Negri Institute, Nordic Cochrane Centre and WEMOS to the European Medicines Agency public consultation on the Draft Reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME). Read on...
"Adaptive licensing" or "adaptive pathways": Deregulation under the guise of earlier access (October 2015)

Joint briefing paper. "Adaptive pathways" raise numerous concerns from a public health perspective. The organisations that endorse this statement have closely monitored developments in EU pharmaceutical regulation for many years and put forward a critique of the "adaptive pathways concept". Implementing adaptive pathways could lead to a situation where premature marketing authorisations become the rule, even when no genuine public health need exists, therefore putting EU citizens' health unnecessarily at risk. Read on...
Marketing authorisation flexibilities that enable early access to medicines should only respond to true unmet medical needs and must protect patients' safety (September 2015)

Joint response to an EMA public consultation on the Guidelines to implement accelerated assessment and conditional marketing authorisation for medicinal products for human use. Read on...
Health groups call on European medicines agencies to address independence and transparency problems (July 2015)

Joint response to an EMA public consultation. The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) are in danger of failing to address urgent public health needs due to a lack of independence and transparency.
Read on...
EU directive on trade secrets: the European Parliament must profoundly improve this text (March 2015)

Joint open letter to the members of the Legal affairs (JURI) Committee of the European Parliament. Amendments are needed to preserve freedom of speech for journalists and whistle-blowers, and access to regulatory and scientific data of public interest. Read on...
EU Clinical Trials Regulation: EMA steers away from transparency by misinterpreting exception provisions (February 2015)

Joint response to an EMA public consultation. The European Medicines Agency (EMA) must stay true to the Clinical Trials Regulation: non-disclosure has to remain the exception, not become the norm! Read on...
European Directive on trade secrets: A threat to access to public health data (February 2015)

Joint briefing paper. The proposed EU directive on the protection of trade secrets currently being studied by the European Parliament threatens freedom of speech for journalists and whistle-blowers, and access to scientific data of public interest. Read on...

2024 Recap
2023 Recap
2022 Recap
2021 Recap
2020 Recap
2019 Recap
2018 Recap
2017 Recap
2016 Recap
2015 Recap
2014 Recap
2013 Recap
2012 Recap
2011 Recap
2008-2010 Recap
2005-2007 Recap
The 2002-2004 campaign

Sitemap |
Terms of use |
Contact
|Top of page